OA13.03 Perioperative Durvalumab for Resectable NSCLC (R-NSCLC): Updated Outcomes from the Phase 3 AEGEAN Trial
2024 · Journal of Thoracic Oncology · 16 citations
https://doi.org/10.1016/j.jtho.2024.09.069
J
Jarosław Kołb-Sielecki
University of Computer Sciences and Economics in Olsztyn(PL)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
13
Papers
523
Citations
6
h-index
3
i10-index
Jarosław Kołb-Sielecki is an academic researcher from University of Computer Sciences and Economics in Olsztyn. The author has contributed to research in topics: Palliative Care and End-of-Life Issues & Lung Cancer Treatments and Mutations & Lymphoma Diagnosis and Treatment. The author has an h-index of 6, co-authored 12 publications.
Papers by this author
worksCancer related information that cancer patients need
2025 · Scientific Reports · 5 citations
https://doi.org/10.1038/s41598-025-99498-4
143P Strength of patient (pt) preference for atezolizumab (atezo) subcutaneous (SC) vs intravenous (IV) for the treatment of NSCLC: Exploratory analyses from the IMscin002 study
2024 · Immuno-Oncology Technology · 0 citations
https://doi.org/10.1016/j.iotech.2024.100772
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat